SEARCH:
Print

Infectious Diseases

Bavarian Nordic focuses on the research, development and manufacture of vaccines to prevent infectious diseases, including biological threats to national security such as smallpox, Ebola and more.

The company utilizes its patented MVA-BN® technology platform to develop a broad infectious disease vaccine pipeline. The lead program is a non-replicating smallpox vaccine based on MVA-BN, licensed in the U.S, the European Union and in Canada.

The company has delivered 28 million doses of the smallpox vaccine to date to the U.S. Strategic National Stockpile for emergency use and is also working with other governments on their smallpox preparedness.